UY33525A - NEW POLYETHYLENGLYCOL, STABLE CONFAUGHT OF ALFA INTERFERON, REPRESENTED BY AN ISOMER OF POSITION - Google Patents

NEW POLYETHYLENGLYCOL, STABLE CONFAUGHT OF ALFA INTERFERON, REPRESENTED BY AN ISOMER OF POSITION

Info

Publication number
UY33525A
UY33525A UY0001033525A UY33525A UY33525A UY 33525 A UY33525 A UY 33525A UY 0001033525 A UY0001033525 A UY 0001033525A UY 33525 A UY33525 A UY 33525A UY 33525 A UY33525 A UY 33525A
Authority
UY
Uruguay
Prior art keywords
new
interferon
stable
ifn
conjugate
Prior art date
Application number
UY0001033525A
Other languages
Spanish (es)
Inventor
Denisov Lev Aleksandrovich
Morozov Dmitriy Valentinovich
Rudenko Elena Georgievna
Klenova Angelina Vsovoldovna
Chernovskaya Tatyana Veniaminovna
Original Assignee
Cjsc Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33525(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cjsc Biocad filed Critical Cjsc Biocad
Publication of UY33525A publication Critical patent/UY33525A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

Nuevos PEG-derivados del interferón y se vincula a la creación de un nuevo conjugado de interferón con polietilenglicol, activo, altamente purificado , estable, a la actividad del interferón alfa, con inmunogenicidad reducida, a una acción biológica prolongada, a parámetros farmacocinéticos mejorados de la fórmula general dónde: n - valores enter os del 227 al 10000; m - número entero Z4; IFN - polipéptido natural o recombinante, con actividad IFN-alfa. Asimismo, se relaciona con fármacos que contienen el conjugado de la fórmula (I), con farmacos, adecuados para tratar enfermedades virales, oncológicas y enfermedades inmunodeficiencia primaria o secundaria, que contienen el conjugado solicitado PEG-IFN y componentes auxiliares.New PEG-derivatives of interferon and is linked to the creation of a new interferon conjugate with polyethylene glycol, active, highly purified, stable, to the activity of interferon alpha, with reduced immunogenicity, to prolonged biological action, to improved pharmacokinetic parameters of the general formula where: n - enter values from 227 to 10000; m - integer Z4; IFN - natural or recombinant polypeptide, with IFN-alpha activity. It also relates to drugs that contain the conjugate of the formula (I), with drugs, suitable for treating viral, oncological and primary or secondary immunodeficiency diseases, which contain the requested PEG-IFN conjugate and auxiliary components.

UY0001033525A 2010-07-20 2011-07-20 NEW POLYETHYLENGLYCOL, STABLE CONFAUGHT OF ALFA INTERFERON, REPRESENTED BY AN ISOMER OF POSITION UY33525A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (en) 2010-07-20 2010-07-20 NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON

Publications (1)

Publication Number Publication Date
UY33525A true UY33525A (en) 2012-02-29

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033525A UY33525A (en) 2010-07-20 2011-07-20 NEW POLYETHYLENGLYCOL, STABLE CONFAUGHT OF ALFA INTERFERON, REPRESENTED BY AN ISOMER OF POSITION

Country Status (20)

Country Link
KR (1) KR101586372B1 (en)
CN (1) CN102617736B (en)
AR (1) AR087227A1 (en)
BR (1) BRPI1101565A2 (en)
CO (1) CO6680611A2 (en)
CR (1) CR20130021A (en)
CU (1) CU24193B1 (en)
DO (1) DOP2013000002A (en)
EA (1) EA020257B1 (en)
EC (1) ECSP13012398A (en)
HK (1) HK1170504A1 (en)
MX (1) MX2011007458A (en)
MY (1) MY168784A (en)
NI (1) NI201300008A (en)
PE (1) PE20131034A1 (en)
RU (1) RU2447083C1 (en)
SG (1) SG187117A1 (en)
UA (1) UA99766C2 (en)
UY (1) UY33525A (en)
WO (1) WO2012011836A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (en) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS)
EA021643B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Monopegylated interferon-alpha of linear structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity
EA021610B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Liquid antiviral formulation
CN103463623B (en) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 A kind of Peg-IFN alpha-2b injection and preparation method thereof
RU2554761C1 (en) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Anti-enteroviral and immunostimulating agent
RU2572800C1 (en) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration
EA029498B1 (en) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ANTI-TUMOUR DRUG BASED ON RECOMBINANT INTERFERON ALPHA-2b IN THE FORM OF MICROPARTICLES FOR PARENTERAL ADMINISTRATION
RU2678332C1 (en) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
CN114392237B (en) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 Freeze-dried virus preparation and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP4764630B2 (en) * 2002-09-09 2011-09-07 ネクター セラピューティックス Water-soluble polymer alkanal
RU2311930C2 (en) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Pagylated interferon against viral infection
JP2008509889A (en) * 2004-06-30 2008-04-03 イージェン コーポレーション PEGylated interferon alpha-1b
KR101334541B1 (en) * 2005-07-19 2013-11-28 넥타르 테라퓨틱스 Method for preparing polymer maleimides
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases
CN101491682A (en) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 PEG-IFN omega conjugate and preparation technique thereof
CN101591387A (en) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 PEG-IFN omega conjugate
CN101514229B (en) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 Human interferon alpha derivative and polyethylene glycol modified substance thereof

Also Published As

Publication number Publication date
HK1170504A1 (en) 2013-03-01
ECSP13012398A (en) 2013-05-31
BRPI1101565A2 (en) 2012-12-04
PE20131034A1 (en) 2013-09-27
RU2447083C1 (en) 2012-04-10
SG187117A1 (en) 2013-02-28
UA99766C2 (en) 2012-09-25
CN102617736A (en) 2012-08-01
AR087227A1 (en) 2014-03-12
CN102617736B (en) 2015-11-25
WO2012011836A1 (en) 2012-01-26
CR20130021A (en) 2013-02-20
CU20130013A7 (en) 2013-04-19
MX2011007458A (en) 2012-01-19
KR20130056885A (en) 2013-05-30
NI201300008A (en) 2014-05-26
MY168784A (en) 2018-12-04
RU2010129824A (en) 2012-01-27
DOP2013000002A (en) 2013-09-15
EA201100809A1 (en) 2012-01-30
CU24193B1 (en) 2016-09-30
CO6680611A2 (en) 2013-05-31
EA020257B1 (en) 2014-09-30
KR101586372B1 (en) 2016-01-18

Similar Documents

Publication Publication Date Title
UY33525A (en) NEW POLYETHYLENGLYCOL, STABLE CONFAUGHT OF ALFA INTERFERON, REPRESENTED BY AN ISOMER OF POSITION
BR112018075465A2 (en) hepatitis b antiviral agents
CO6501124A2 (en) IMMUNOMODULATING POLYPEPTIDES DERIVED IS THE IL 2 AND ITS THERAPEUTIC USE IN CANCER AND IN CHRONIC INFECTIONS
BR112013032717A2 (en) glucagon / glp-1 receptor coagonists
EA201490521A1 (en) OPTIONS OF FIBROBLAST GROWTH FACTOR 21
EA201490801A1 (en) COMPOSITES ЭТАНЕРЦЕПТА, СТАБИЛИЗИРОВАННЫЕ КОМБИНЦИЯЯ САХАРОВ И ПОЛИОЛОВ
BR112013031268A8 (en) polypeptides
CL2011000170A1 (en) Solid and stabilized pharmaceutical composition comprising a pharmaceutically active ingredient, titanium oxide and a plasticizer; procedure to stabilize the pharmaceutical composition during a light irradiation.
CL2011000571A1 (en) Use of a combination of: a) a compound of formula (1) or a pharmaceutically acceptable salt thereof, b) interferon alfa and c) ribavirin to prepare a medicament useful for the treatment of a viral infection of hepatitis c (hcv) or to relieve one or more symptoms of it.
EP3967323A3 (en) Hiv vaccine
MD4736B1 (en) Polycyclic carbamoylpyridone compound and its pharmaceutical use
BR112012011128A2 (en) pharmaceutical composition comprising a glp-1 agonist, an insulin and a methionine
EA201290964A1 (en) Peptide Conjugates of GLP-1 Receptor Agonists and Their Use
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EA201492290A1 (en) COMPOSITIONS AND METHODS FOR VAGINAL DELIVERY OF ANTIPROGHESTINES
DOP2012000132A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES AN GLP-1 AND METIONINE AGONIST
CL2012001959A1 (en) Compounds derived from thiophene-2-carboxylic acid, flaviviridae virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment of a viral infection by flaviviridae.
EA201490213A1 (en) BENZOFURANE CONNECTIONS FOR THE TREATMENT OF INFECTIONS BY THE HEPATITIS C VIRUS
ECSP14023048A (en) OPTIMIZED THERAPEUTIC AGENTS FOR SUBCUTANEOUS ADMINISTRATION
ECSP11011101A (en) CYCLOUNDECADEPSIPEPTIDE COMPOUNDS AND THE USE OF SUCH COMPOUNDS AS A MEDICINAL PRODUCT
CO2020008308A2 (en) Modified lipidated relaxin b-chain peptides and their therapeutic use
CR11734A (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
AR114323A1 (en) MODIFIED RELAXIN B-CHAIN PEPTIDES AND THEIR THERAPEUTIC USE
AR089812A1 (en) THERAPEUTIC AGENT FOR MELLITUS DIABETES
BR112014009165A2 (en) salt and medical use